EgyptTuberculosis profile
Population  2014 90 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.22 (0.2–0.25) 0.25 (0.22–0.27)
Mortality (HIV+TB only) 0.043 (0.035–0.051) 0.05 (0.04–0.06)
Prevalence  (includes HIV+TB) 23 (12–37) 26 (13–42)
Incidence  (includes HIV+TB) 13 (12–15) 15 (13–16)
Incidence (HIV+TB only) 0.035 (0.028–0.044) 0.04 (0.03–0.05)
         
Case detection, all forms (%) 54 (49–60)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 3.4 (1.9–4.9) 15 (12–18)
MDR-TB cases among notified pulmonary
TB cases
160 (87–220) 89 (72–110)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 3 697   309
Pulmonary, clinically diagnosed 886   0
Extrapulmonary 2 285   0
       
Total new and relapse 7 177    
Previously treated, excluding relapses 290    
Total cases notified 7 467    
Among 6 868 new cases:
429 (6%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 45 (1%) 358 (60%) 403
Laboratory-confirmed RR-/MDR-TB cases     86
Patients started on MDR-TB treatment ***     72
TB/HIV 2014 Number (%)
TB patients with known HIV status 1 690 (23)
HIV-positive TB patients 12 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 12 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 12 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (86) 7 876
Previously treated cases, excluding relapse, registered in 2013 (72) 307
HIV-positive TB cases, all types, registered in 2013 (29) 7
RR-/MDR-TB cases started on second-line treatment in 2012 (63) 52
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 1.0
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-25 Data: www.who.int/tb/data